MedTrace Logo

Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or Pantoprazole

NCT06991348 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2025-07-23

No results posted yet for this study

Summary

The objective of this clinical trial is to compare which of the two drugs best resolves symptoms in patients diagnosed with erosive and non-erosive gastroesophageal reflux disease, adult males and females. The main question is What is the proportion of patients with resolution of the main symptoms of gastroesophageal reflux disease at four weeks of treatment with pantoprazole vs tegoprazan.

Conditions

  • Gastroesophageal Reflux Disease

Interventions

DRUG

Tegoprazan

Tegoprazan 50 mg daily for 28 days

DRUG

Pantoprazole

Pantoprazole 40 mg daily for 28 days

Sponsors & Collaborators

  • Carnot Laboratories

    lead INDUSTRY

Principal Investigators

  • Jose M Remes-Troche, Dr · Digestive Physiology and Motility Lab, Instituto de Investigaciones Médico Biológicas, Veracruz , México

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-30
Primary Completion
2025-11-30
Completion
2025-11-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06991348 on ClinicalTrials.gov